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Abstract
High on-treatment platelet reactivity (HPR) by ADP, which primarily reflects the effect of thienopyridines, has been found to
be an independent predictor of ischemic events in patients with acute coronary syndrome (ACS) on dual antiplatelet therapy.
CYP2C19*2 is associated with HPR by ADP. The aim of our study was to evaluate if high on-clopidogrel platelet reactivity
(HPR) by ADP is associated with an increased risk of major adverse coronary events (MACE) after ACS independent of
CYP2C19*2 allele, i.e. whether genotyping patients for CYP2C19*2 polymorphism is sufficient to identify those to be
switched to novel antiplatelets. A total of 1187 patients were included (CYP2C19 *1/*1 n¼ 892; *1/*2 n¼ 264; *2/*2
n¼ 31); 76 MACE (CV death and non-fatal MI) were recorded in non-carriers of CYP2C19*2 (8.5%) and 39 in carriers of
CYP2C19*2 (13.2%). At the landmark analysis in the first 6 months, HPR by ADP and CYP2C19*2 allele were both
significantly and independently associated with MACE [HPR by ADP: HR¼ 2.0 (95% CI 1.2–3.4), p¼ 0.01; CYP2C19*2
allele: HR¼ 2.3 (95% CI 1.3–3.9), p¼ 0.003]. At the land mark analysis from 7 to 12 months, only HPR by ADP remained
significantly associated with the risk of MACE [HPR by ADP: HR¼ 2.7 (95% CI 1.4–5.3), p¼ 0.003; CYP2C19*2:
HR¼ 0.8 (95% CI 0.2–1.1), p¼ns]. CYP2C19*2 allele and HPR by ADP are both independently associated with an
increased risk of MACE in the first 6 months after ACS. HPR by ADP is associated with an increased risk until 12 months of
follow-up. Therefore, both phenotype and genotype are clinically relevant for the evaluation of the antiplatelet effect of
clopidogrel and for the prognostic stratification of ACS patients.
Keywords: High on-treatment platelet reactivity, cardiovascular death, non-fatal myocardial infarction, clopidogrel,
CYP2C19*2 polymoprhism, acute coronary syndrome
Introduction
High on-treatment platelet reactivity (HPR) by ADP,
which primarily reflects the effect of thienopyridines,
has been found to be an independent predictor of
ischemic events in patients with acute coronary
syndrome (ACS) on dual antiplatelet therapy
[1–13]. Clopidogrel is a prodrug and, among the
different CYP450 isoenzymes involved in its metab-
olism, CYP2C19 has an important role in its
conversion to the active metabolite [14]. Recently,
a single nucleotide polymorphism (CYP2C19*2) has
been associated with the inactivation of the enzyme
and an impaired metabolism of clopidogrel [14]. The
CYP2C19*2 loss-of-function polymorphism is a
G681A nucleotide substitution that introduces a
splicing defect resulting in a truncated, non-func-
tional protein responsible for the poor metabolizer
phenotype [15]. Different groups have contemporar-
ily demonstrated that CYP2C19*2 is associated with
HPR by ADP and is a per se determinant of the
occurrence of major adverse cardiac events (MACE)
in percutaneous coronary intervention (PCI) patients
on clopidogrel treatment [16–23].
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On the other hand, available data demonstrate
that HPR by ADP is associated with clinical and
biological characteristics, such as advanced age,
diabetes, cardiac failure, the entity of platelet
turnover and of inflammatory state [24–26].
Searching for a good tool to identify patients at
high risk of recurrences who might need the new,
more potent, antiplatelet agents such as prasugrel
and ticagrelor, clinicians have the possibility to
investigate the phenotype – HPR by ADP – or
genotype – CYP2C19*2 polymorphism. The utility
of genetic tests to identify differences in CYP2C19
function has been highlighted by the ‘boxed warning’
issued of the Food and Drug Administration advising
healthcare professionals to consider use of other
antiplatelet medications or alternative dosing strate-
gies for clopidogrel in these patients [27].
The aim of our study was to evaluate if HPR by
ADP is associated with MACE even in the absence of
CYP2C19*2 allele, i.e. whether genotyping patients
for CYP2C19*2 polymorphism is sufficient to
identify those with platelet hyperreactivity to be
switched to novel antiplatelet drugs.
Materials and methods
Study population
Patients with ACS who underwent PCI and with an
anticipated non-adherence to dual antiplatelet treat-
ment for at least 6 months were considered eligible
for the study. Informed written consent was obtained
from all patients, and the study was approved by the
local Ethical Review Board.
PCI and antiplatelet management
All interventions were performed according to the
current standard guidelines, and the type of stent
implanted and the use of IIb/IIIa inhibitors were at
the discretion of the operator. All patients received
one clopidogrel loading dose of 600mg followed by a
daily dose of 75mg. All patients received unfrac-
tioned heparin 70 IU/Kg during the procedure and
acetylsalicylic acid i.v. 500mg followed by a daily
dose of 100–325mg by oral route according to the
current guidelines for PCI.
CYP2C19*2 polymorphism
Genomic DNA was extracted from whole blood
specimens with the use of GeneCatcherTM kit
(Invitrogen) automated on the Tecan Freedom
EVO platform (Tecan) according to the manufac-
turers’ recommendations. Genotyping for *2 variant
of CYP2C19 (rs4244285) was performed with the
use of an allelic discrimination assay and the detec-
tion system – ABI prism 7900HT Sequence
Detection System (Applied Biosystems). Allele def-
inition follows the nomenclature of the Human
Cytochrome P450 (CYP) Allele Nomenclature
Committee (www.cypalleles.ki.se).
Platelet reactivity assessment
Venous blood samples anticoagulated with 0.109M
sodium citrate (ratio 9:1) were taken from each
patient within 24 h from 600mg clopidogrel loading.
For patients receiving in the catheterization labora-
tory both the loading dose of clopidogrel and a IIb/
IIIa inhibitor, blood samples were obtained 6 days
after while the patients were on the 75mg mainte-
nance dose of clopidogrel.
Platelet-rich plasma, obtained by centrifuging
whole blood for 10min at 200 g, was stimulated
with 10 mmol ADP (Mascia Brunelli, Milan, Italy)
and aggregation was assessed using a APACT 4
light transmission aggregometer (LTA; Helena
Laboratories, Milan, Italy) as previously
reported [28].
Data collection and follow-up
All data were prospectively collected and entered in a
central database. Clinical follow-up information was
obtained by contacting all patients at 12 months, and
source documents of potential events were obtained.
Endpoints: (1) cardiovascular (CV) death, defined
as death in the presence of ACS, significant cardiac
arrhythmia or refractory cardiac heart failure; (2)
non-fatal myocardial infarction (MI) (a rise in serum
troponin I and/or an increase in creatine kinase MB
isoenzyme at least twice the upper normal limits with
at least one of the following: acute onset of prolonged
(20min) typical ischemic chest pain; ST-segment
elevation of at least 1mm in two or more contiguous
electrocardiographic leads or ST-depression of
0.5mm in 2 contiguous leads).
Statistical analysis
Continuous variables are presented as median
(range) or mean and SD as appropriate.
Categorical data are reported as frequencies.
Differences in continuous variables were compared
by Student’s t-test or Mann–Whitney U test, as
appropriate. Dichotomous variables were compared
by 2 test or Fisher’s Exact test, as appropriate.
A receiver operating characteristic (ROC) curve
analysis was used to determine the ability of 10 mmol
ADP to distinguish between patients with and
without post-discharge events after PCI.
Cumulative survival curves for both patients with
and without HPR (as defined by 10 mmol ADP LTA
55% [29]) were constructed by the Kaplan–Meier
(KM) method in patients who are carriers and
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non-carriers of CYP2C19*2 allele. A landmark
analysis was computed by the KM method for CV
death and non-fatal MI from 0 to 6 months and from
7 to 12 months. We selected the 6-month point as a
landmark according to the prespecified exclusion
criterion of anticipated non-adherence to dual
antiplatelet treatment for at least 6 months.
Univariate and multivariate regression analyses
were used, respectively, to identify risk factors for
clinical end points and to adjust for potential
confounders (CV risk factors, renal failure, left
ventricular ejection fraction (LVEF) <40%, multi-
vessel disease, total stent length, bifurcation lesions,
number of lesions treated and type of stent (BMS or
DES), use of GpIIb/IIIa inhibitors and aspirin
dosage). McNamar test was used to compare
specificity between different aggregometry tests. A
significant level was defined when p< 0.05. All
analysis was performed using SPSS 10.0 (SPSS
Inc., Chicago, IL).
Results
A total of 1218 patients with ACS were recruited.
Among these patients, 1187 were included in this
analysis, while 31 were excluded for the following
reasons: anticipated non-adherence to dual antipla-
telet treatment, refusal to participate and non-
availability of platelet function tests because of
thrombocytopenia (Figure 1); 1187 (882 M/305 F)
patients with ACS undergoing PCI with stent
implantation were included. Genotype distribution
of CYP2C19*2 polymorphism was as follows: *1/*1
n¼ 892; *1/*2 n¼ 264; and *2/*2 n¼ 31 (Hardy–
Weinberg equilibrium: 2¼ 2.095, p¼ 0.35). As
expected, LTA by 10 mmol ADP was significantly
higher in patients who are carriers of *2 allele with
respect to the others: 52.5% 19.9% vs. 46.8%
21.7%, p< 0.0001.
Baseline characteristics are given in Tables I
and II. The 1-year follow-up rate was 100%. One
hundred and fifteen MACE were recorded: 76 events
in non-carriers of CYP2C19*2 (8.5%) and 39 events
in carriers of CYP2C19*2 (13.2%). Ten micromol
ADP LTA values were significantly higher in patients
with the subsequent occurrence of CV death and
non-fatal MI in both groups (Tables I and II).
Clinical characteristics according to the occurrence
of CV deaths and non-fatal MI in carriers and
Table I. Clinical characteristics of patients investigated – non-carriers of CYP2C19*2.
Overall group
(n¼ 892)
12-month follow-up
MACE (n¼ 76)
12-month follow-up
No MACE (n¼816) pa
Age, years 69 (32–93) 69 (52–90) 69 (32–93) 0.006
Male gender, n (%) 672 (75.3) 54 (71) 618 (75.7) 0.2
Diabetes, n (%) 219 (24.6) 21 (27.6) 198 (24.3) 0.1
Smoking, n (%) 327 (36.7) 29 (38.2) 298 (36.5) 0.3
Hypertension, n (%) 580 (65.0) 48 (63.2) 532 (65.2) 0.4
Dyslipidemia, n (%) 483 (54.1) 41 (53.9) 442 (54.2) 0.4
LVEF <40%, n (%) 233 (36.1) 24 (31.6) 209 (25.6) 0.01
Renal failureb, n (%) 80 (9.0) 7 (9.2) 73 (8.9) 0.4
STEMI, n (%) 318 (35.7) 29 (38.1) 289 (35.4) 0.4
ACE-inhibitors, n (%) 598 (67.0) 52 (68.4) 554 (67.9) 0.9
Beta-blockers, n (%) 357 (40.0) 31 (40.7) 334 (40.9) 0.8
Statins, n (%) 562 (63) 48 (63.1) 514 (62.9) 0.8
Pump inhibitors, n (%) 829 (93) 70 (92.1) 759 (93) 0.8
Glycoprotein IIb/IIIa, n (%) 357 (40) 29 (38.1) 326 (39.9) 0.5
Vessels treated, n 1328 155 1173 –
Drug eluting stent, n (%) 156 (17.5) 16 (21) 142 (17.4) 0.2
Bifurcation lesion, n (%) 366 (41) 31 (40.7) 335 (41) 0.6
Total stent length (mm) 34.522.3 33.6 22.6 34.5 22.3 0.4
LTA by 10 mmol ADP 46.821.7 55.8 21.4 45.9 21.5 0.001
Notes: MACE¼CV death and non-fatal MI.
aMACE vs. no MACE and brenal insufficiency defined by creatinine levels above 2.0mg/dl.
31 excluded
anticipated nonadherence to
dual antiplatelet treatment (including
patients with STEMI who died in hospital)
1187 patients included
nonavailability of platelet test
Figure 1. Study flow.
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Figure 2. ROC curve for LTA by 10 mmol ADP.
Table II. Clinical characteristics of patients investigated – carriers of CYP2C19*2 (*1/*2þ *2/*2).
Overall group
(n¼ 295)
12-month follow-up
MACE (n¼ 39)
12-month follow-up
No MACE (n¼ 256) pa
Age, years 69 (29–94) 71 (29–85) 69 (36–94) 0.001
Male gender, n (%) 216 (73.2) 30 (76.9) 183 (71.4) 0.2
Diabetes, n (%) 66 (22.3) 13 (33.3) 53 (20.7) 0.1
Smoking, n (%) 108 (36.6) 16 (41) 92 (35.9) 0.3
Hypertension, n (%) 197 (66.7) 28 (71.7) 169 (66) 0.4
Dyslipidemia, n (%) 163 (55.2) 20 (51.2) 143 (55.8) 0.4
LVEF <40%, n (%) 75 (25.4) 12 (30.1) 63 (24.6) 0.05
Renal failureb, n (%) 26 (8.8) 3 (7.6) 23 (8.9) 0.4
STEMI, n (%) 101 (34.2) 13 (33.3) 88 (34.4) 0.2
ACE-inhibitors, n (%) 195 (66) 27 (69.2) 168 (65.6) 0.8
Beta-blockers, n (%) 114 (38.6) 16 (41) 98 (38.2) 0.5
Statins, n (%) 191 (64.7) 25 (64.1) 166 (64.8) 0.4
Pump inhibitors, n (%) 285 (96.6) 36 (92.3) 249 (97.2) 0.3
Glycoprotein IIb/IIIa, n (%) 115 (38.9) 15 (38.4) 100 (39.0) 0.8
Vessels treated, n 439 79 360 –
Drug eluting stent, n (%) 54 (18.3) 8 (20.5) 46 (17.9) 0.1
Bifurcation lesion, n (%) 94 (31.8) 14 (35.8) 80 (31.2) 0.8
Total stent length (mm) 35.6 26.9 33.6 22.6 34.522.3 0.4
LTA by 10 mmol ADP 52.5 19.9 61.6 17.6 51.119.9 0.001
Note: As in notes of Table I.
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non-carriers of CYP2C19*2 are reported in Tables I
and II.
ROC curve analysis demonstrated that 10mmol
ADP LTA was able to distinguish between patients
with and without subsequent CV death and non-fatal
MI at 12-month follow-up both in carriers and non-
carriers of CYP2C19*2 (Area under the curve 0.66
(0.57–0.75), p< 0.001 and 0.64 (0.57–0.71),
p< 0.001, respectively) (Figure 2).
The event-free survival curves for CV death and
non-fatal MI according to *2 allele carriers vs. non-
carriers are shown in Figure 3(b) (10 mmol ADP
LTA in CYP2C19 *1/*1¼ 46.8% 21.7%; *1/
*2¼ 51.3% 19.6%; and *2/*2¼ 63.2% 19.3%).
In Figure 3(a), (c), and (d), KM curves according to
HPR vs. non-HPR both in carriers and non-carriers
of CYP2C19*2 allele are reported.
The landmark analysis (0–6 months and 7–12
months) showed that the differences between HPR
and non-HPR groups in CV death and non-fatal MI
emerged both in the short-term follow-up (Figure 4)
as well as later on (Figure 5). On the other hand,
carriers of CYP2C19*2 were associated with a
significant higher risk until 6 months (Figure 4),
but not between 6 and 12 months (Figure 5).
Patients with LTA by ADP 55%, which we
previously demonstrated to be the optimal cut-off for
detection of ischemic recurrences [29], were signif-
icantly older, more likely to be female, diabetic and
with reduced LVEF with respect to patients without
RPR (Table III).
At the land mark analysis in the first 6 months
(0–6), HPR by ADP and CYP2C19*2 allele were
both significantly and independently associated with
a higher risk of CV death and non-fatal MI after
adjustment for CV risk factors, renal failure, reduced
ejection fraction, multivessel disease, total stent
length, bifurcation lesions, number of lesions treated,
type of stent and use of GpIIb/IIIa inhibitors [HPR
by ADP: HR¼ 2.0 (95% CI 1.2–3.4), p¼ 0.01;
CYP2C19*2 allele: HR¼ 2.3 (95% CI 1.3–3.9),
p¼ 0.003]. The presence of both – HPR by ADP and
CYP2C19*2 allele – was associated with a higher
risk: HR¼ 2.7 (1.5–5.1), p< 0.001.
At the land mark analysis from 7 to 12 months,
only HPR by ADP remained significantly associated
Figure 3. KM survival curves for CV death and non-fatal MI.
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with the risk of MACE at the Cox regression analysis
adjusted for CV risk factors, renal failure, reduced
ejection fraction, multivessel disease, total stent
length, bifurcation lesions, number of lesions treated,
type of stent and use of GpIIb/IIIa inhibitors [HPR
by ADP: HR¼ 2.7 (95% CI 1.4–5.3), p¼ 0.003;
CYP2C19*2: HR¼ 0.8 (95% CI 0.2–1.1), p¼ns].
Discussion
In this analysis, we demonstrate that HPR by ADP is
a risk factor for clinical recurrences in ACS patients
on dual antiplatelet treatment, even in the absence of
CYP2C19*2 allele.
The history of the ‘resistance’ to clopidogrel
moves from the studies which found an association
between HPR by ADP and risk of vascular
complications, i.e. stent thrombosis, CV death and
non-fatal MI [1–16]. Subsequently, different
researchers, including our group, studied the possi-
ble genetic determinants of response to clopidogrel
focusing on the presence of polymorphisms in genes
coding for CYP450 enzymes [17]. It has been
detected that CYP2C19*2 polymorphism is associ-
ated with HPR by ADP and it is per se associated with
vascular risk [18–24]. Furthermore, we found that
both HPR by ADP and CYP2C19*2 polymorphism
were independently associated with the occurrence of
stent thrombosis and CV death [23] at a 6-month
follow-up.
Indeed, both genotype – CYP2C19*2 allele – and
phenotype – HPR by ADP – are available in order to
identify patients who might need a more potent
platelet inhibition, potentially by the new antiplatelet
drugs such as prasugrel or ticagrelor.
The question to be answered is if the issue of
platelet hyperreactivity on treatment is a phenome-
non to be restricted, in the clinical practice, to the
problem of the metabolism of clopidogrel.
The recent ‘‘boxed warning’’ of FDA underlines
the importance of CYP2C19*2 polymorphism
for the choice of alternative drugs to clopidogrel [27].
For this purpose, we have decided to evaluate
the risk of clinical recurrences according to HPR
by ADP in carriers and non-carriers of
Figure 4. KM landmark analysis survival curves for CV death and non-fatal MI (0–6 months).
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Figure 5. KM landmark analysis survival curves for CV death and non-fatal MI (7–12 months).
Table III. Clinical characteristics according to HPR by ADP (10mmol ADP LTA 55%).
Non-carriers of CYP2C19*2 Carriers of CYP2C19*2
HPR by
ADP (n¼ 342)
No HPR by
ADP (n¼ 550) p
HPR by
ADP (n¼ 144)
No HPR by
ADP (n¼ 151) p
Age, years 69 (46–93) 69 (32–93) <0.05 73 (29–90) 67 (36–94) <0.005
Male gender, n (%) 250 (73) 422 (76.7) <0.05 104 (72.2) 112 (74.1) <0.05
Diabetes, n (%) 90 (26.3) 129 (23.5) <0.001 40 (27.7) 26 (17.2) <0.0001
Smoking, n (%) 120 (35.1) 207 (37.6) 0.4 55 (38.2) 53 (35.1) 0.04
Hypertension, n (%) 240 (70.2) 340 (61.8) 0.5 98 (68) 99 (65.5) 0.3
Dyslipidemia, n (%) 171 (50) 312 (56.7) 0.2 75 (52.1) 88 (58.3) 0.4
LVEF <40%, n (%) 91 (26.6) 142 (25.8) <0.001 38 (26.4) 37 (24.5) <0.05
Renal failurea, n (%) 23 (6.7) 57 (10.4) 0.4 10 (6.9) 16 (10.6) 0.4
STEMI, n (%) 104 (30.4) 176 (32) <0.001 36 (25) 65 (43) <0.001
ACE-inhibitors, n (%) 229 (66.9) 374 (68) 0.3 96 (66.6) 99 (65.6) 0.2
Beta-blockers, n (%) 140 (40.9) 225 (40.9) 0.3 59 (40.9) 55 (36.4) 0.5
Statins, n (%) 215 (62.8) 346 (62.9) 0.1 91 (63.2) 100 (66.2) 0.09
Pump inhibitors, n (%) 318 (92.9) 511 (92.9) 0.2 136 (94.4) 149 (98.6) 0.07
Glycoprotein IIb/IIIa, n (%) 140 (40.9) 214 (38.9) 0.9 59 (40.9) 56 (37) 0.8
Vessels treated, n 514 814 – 216 223 –
Drug eluting stent, n (%) 74 (21.6) 83 (15) <0.01 32 (22.2) 22 (14.5) <0.005
Bifurcation lesion, n (%) 145 (42.3) 221 (40.2) 0.2 52 (36.1) 42 (27.8) 0.2
Total stent length (mm) 35.521.6 33.8 22.7 <0.01 39.1 29.9 31.9 23.5 <0.001
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CYP2C19*2 allele. If the problem of HPR by ADP is
only associated with clopidogrel metabolism, we
should find that HPR in the absence of
CYP2C19*2 allele is not associated with an
increased risk of recurrences.
Conversely, our data demonstrate that the pres-
ence of CYP2C19*2 allele confers a higher risk in the
first months after the acute event, and HPR by ADP
also later on. These data are in line with those
obtained in the meta-analysis by Mega et al. [23], in
which the authors failed to find a significant
association between CYP2C19*2 allele and MACE
in landmark analyses from 31 days until the end of
follow-up.
HPR on treatment is a complex phenomenon for
which pharmacogenetic accounts only in part.
In other words, these findings demonstrate that
the entity of platelet inhibition on treatment is a
prognostic factor in ACS patients, independent of
the variability associated with clopidogrel
metabolism.
Accordingly, both genotype and phenotype are
clinically relevant:
(1) Genotyping patients for CYP2C19*2 allele
allows us to identify patients who immediately
need an alternative drug to clopidogrel, inde-
pendent of the clinical characteristics and clinical
manifestation of the disease.
(2) Phenotyping patients for the entity of platelet
inhibition by ADP allows us to obtain an
information about a factor which maintains its
prognostic role until 12 months after the acute
event. Available evidence tells us that we have to
obtain a platelet inhibition which might be
around 55% to reduce the risk of ischemic
recurrences.
The main limitation of our study is the lack of
information on the occurrence of stent thrombosis.
Furthermore, this study includes only a genetic
determinant of HPR by ADP. A number of genetic
polymorphisms are under evaluation to determine
their possible role in affecting the entity of platelet
inhibition on treatment. Nevertheless, till now,
only CYP2C19*2 allele has been consistently
associated with the intermediate phenotype ‘HPR
by ADP’ and with a significantly increased vascular
risk [18–23].
Furthermore, we are aware that platelet reactivity
at the time of ACS may be affected by a number of
clinical and laboratory parameters, including the
high level of the inflammatory state and the increased
platelet turnover [24–26]. Consequently, a percent-
age of patients with platelet hyperreactivity in the
acute state might subsequently return to an adequate
platelet inhibition. The issue of the durability of HPR
remains to be solved by ad hoc studies. Nevertheless,
our results underline the concept that antiplatelet
therapy, driven by the determination of the pheno-
type HPR, might be modulated not only with respect
to the type of the disease, but also with respect to the
different phases of the same disease (acute vs.
chronic phase) suggesting the need of checking the
persistence of HRP over the time.
In conclusion, we found that HPR by ADP is
associated with an increased risk of 12-month follow-
up MACE even in the absence of the genetic
polymorphism – CYP2C19*2 - associated with a
reduced metabolism of clopidogrel. Therefore, both
phenotype and genotype are clinically relevant for the
evaluation of the antiplatelet effect of clopidogrel and
for the prognostic stratification of ACS patients.
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